RxDoctor Payments Data

Dylan Dinesh, MD

Hospitalist · Saint Petersburg, FLNPI 1962996231

Payments from drug & device makers

$792in general payments, 2019–2025

Across 10 payments — averaging $79.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$147
  • Procept Biorobotics Corporation$126
  • Johnson & Johnson$124
  • AstraZeneca$117
  • Medtronic$114
  • AbbVie$112
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$792 in reported general payments places this provider in the 80th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$413,393
Medicare patients
663
Services billed
3,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$64,979
OzempicSemaglutide21$21,432
NuedextaDextromethorphan Hbr/Quinidine23$17,415
LinzessLinaclotide25$13,722
ErtapenemErtapenem Sodium22$10,595
Daptomycin12$10,565
JardianceEmpagliflozin30$10,463
Combivent RespimatIpratropium/Albuterol Sulfate16$8,067
JanuviaSitagliptin Phosphate18$7,897
Vilazodone Hcl11$5,658
Divalproex Sodium114$5,302
LumiganBimatoprost19$4,932
Mirtazapine116$4,820
Midodrine Hcl52$4,695
BreynaBudesonide/Formoterol Fumarate20$4,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Lumigan$112$18,65344 claims
AstraZenecaBrilinta, Symbicort$117$8,09128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →